TVRD — Tvardi Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1346830 ·
Last close
$1.01
Market Cap
$13.47M
52W High
$5.69
52W Low
$0.77
ADV30
290,556
Next earnings
2026-11-13
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -6,328,000 -6,124,000 23,533,000 22,275,000 8,077,000
Jun 2026 0 — -6,629,000 -6,457,000 17,517,000 15,765,000 9,135,000
Mar 2026 0 — -7,051,000 -6,804,000 25,817,000 19,851,000 11,312,000
Dec 2025 0 — -7,587,000 -7,275,000 32,073,000 20,734,000 11,127,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-25,029,000
Investing CF
$20,467,000
Financing CF
$-321,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.79
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-123,711,000
Inventory
$900,000
Receivables
$2,238,000
ST Investments
$0
EBIT TTM
$-27,205,000
Pretax Income TTM
$-26,063,000
Interest Exp TTM
$2,867,000
Analysts
8

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -26,748,000 -18,214,000 32,073,000 11,127,000 20,946,000 -23,499,000
Dec 2024 0 -28,107,000 -29,397,000 35,199,000 126,330,000 -91,131,000 -18,305,000
Dec 2023 0 -18,665,000 -17,347,000 27,001,000 89,059,000 -62,058,000 -21,040,000
Dec 2022 0 -21,193,000 -20,542,000 45,097,000 90,148,000 -45,051,000 -17,866,000

TTM Snapshot

Revenues TTM
$-2,569,000
NetIncome TTM
$-30,736,000
OpCashFlow TTM
—
Assets (Latest)
$17,517,000
Forward EPS
$-1.88

Peers — same industry

TickerNameMarket CapLastDaily %
SYBX SYNLOGIC, INC. $13.47M $1.10 —
ALLR Allarity Therapeutics, Inc. $13.38M $0.84 —
ONCO Onconetix, Inc. $13.14M $3.00 —
ACTU ACTUATE THERAPEUTICS, INC. $13.84M $0.25 —
AKTX Akari Therapeutics Plc $13.03M $5.70 —

News headlines (Yahoo Finance, 1h cache)

Tvardi: Q3 Earnings Snapshot
2026-11-13 12:09 · Yahoo
Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update
2026-11-13 12:00 · Yahoo
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
2026-10-14 12:00 · Yahoo
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
2026-09-24 12:00 · Yahoo
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
2026-07-30 11:30 · Yahoo
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
2026-05-08 11:00 · Yahoo
Tvardi Therapeutics to Participate in Upcoming Investor Events
2026-05-21 12:00 · Yahoo
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
2026-04-02 12:00 · Yahoo
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
2026-03-31 20:01 · Yahoo
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
2026-07-07 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.